Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.60 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937770 | 0.89 | HCAR3 (0.57) | NNMTHCAR3EPHX2SMN1; SMN2DPP4 | |
| SCHEMBL30492154 | 0.89 | NNMT (0.58) | NNMTHCAR3EPHX2SMN1; SMN2DPP4 | |
| SCHEMBL3562313 | 0.87 | HCAR3 (0.71) | HCAR3 | |
| SCHEMBL31058294 | 0.87 | HCAR3 (0.71) | HCAR3 | |
| SCHEMBL13043454 | 0.83 | HCAR3 (0.57) | NNMTHCAR3 | |
| SCHEMBL12953967 | 0.81 | HCAR3 (0.76) | NNMTHCAR3EPHX2 | |
| SCHEMBL1680894 | 0.81 | HCAR3 (0.76) | NNMTHCAR3EPHX2 | |
| SCHEMBL3465091 | 0.81 | NNMT (0.58) | NNMTHCAR3EPHX2 | |
| SCHEMBL11546416 | 0.81 | HCAR3 (0.73) | NNMTHCAR3EPHX2SMN1; SMN2 | |
| SCHEMBL6637382 | 0.79 | PRKAB2 (0.56) | NNMTHCAR3EPHX2SMN1; SMN2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102020638-B | 2-indolinone derivative with protein kinase inhibition activity and histone deacetylase inhibition activity and preparation method and application thereof | SHENZHEN CHIPSCREEN BIOSCIENCES LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-102020607-B | 6-aminoniacinamide derivatives with histone deacetylase inhibiting activity, preparation method and application thereof | SHENZHEN CHIPSCREEN BIOSCIENCES LTD | 2013-01-23 | — | — | CN | disclosed |
| CN-102020607-A | 6-aminoniacinamide derivatives with histone deacetylase inhibiting activity, preparation method and application thereof | SHENZHEN CHIPSCREEN BIOSCIENCES LTD | 2011-04-20 | — | — | CN | disclosed |
| CN-102020638-A | 2-indolinone derivative with protein kinase inhibition activity and histone deacetylase inhibition activity and preparation method and application thereof | SHENZHEN CHIPSCREEN BIOSCIENCES LTD | 2011-04-20 | — | — | CN | disclosed |
| CN-100371323-C | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-02-27 | — | — | CN | disclosed |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| CN-1298703-C | Cyanopyrrolidine Derivatives | TAISHO PHARMACENTICAL CO LTD (JP) | 2007-02-07 | — | — | CN | disclosed |
| EP-1746086-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| CN-1772733-A | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-05-17 | — | — | CN | disclosed |
| CN-1715269-A | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-01-04 | — | — | CN | disclosed |
| US-20040072892-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| CN-1474809-A | Cyanopyrrolidine Derivatives | ������ҩ��ʽ���� | 2004-02-11 | — | — | CN | disclosed |
| EP-1333025-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| WO-1998003485-A1 | PHENOXYPROPANOLAMINES HAVING β3-ADRENERGIC ANTAGONIST ACTIVITY | SANOFI (FR) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072892-A1 | Cyanopyrrolidine derivatives | CCR9, OPRD1, CBR1 | NNMT 2115/4885HCAR3 251/4885EPHX2 3438/4885 |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | DPP4, DPP9, DPP3 | NNMT 1109/4885HCAR3 454/4885EPHX2 3743/4885 |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | CBR3, CBR1, TERT | NNMT 1709/4885HCAR3 708/4885EPHX2 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.